Company
PhoenixBio Co. Ltd
Headquarters: Higashihiroshima, Japan
Employees: 69
CEO: Takashi Shimada
Market Cap
¥1.84 Billion
JPY as of Jan. 1, 2024
US$13.0 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments. Its contract study services in the field of drug discovery and development includes DMPK studies; safety studies; viral hepatitis-related studies; efficacy and safety studies for human specific nucleic acids, antibody, or polypeptide medicines; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
PhoenixBio Co. Ltd has the following listings and related stock indices.
Stock: JPX: 6190 wb_incandescent